Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07271251 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Research Study to See if Two Different Formulations of Oral Semaglutide Are Equally Safe and Effective in Reducing the Blood Sugar Level in Japanese People With Type 2 Diabetes

StatusCompleted
PhasePhase 3
Started2025-12-01
View on ClinicalTrials.gov ↗
The purpose of the study is to find out if the new tablet formulation oral semaglutide D is equally safe and effective as the approved oral semaglutide for treating Japanese people with type 2 diabetes. Participants will receive either oral semaglutide D (the treatment being tested) or oral semaglutide (the comparator); which treatment a participant gets is decided by chance. Oral semaglutide is an approved tablet (a treatment used as a comparator), while oral semaglutide D is described as the new tablet formulation being tested in this study. The study will last approximately 27 weeks.

Amendment history 3 changes detected by DataLookout

2026-08-14
Trial completed
2026-04-01
Trial status changed: Recruiting → Active, Not Recruiting
2026-04-01
Primary completion moved earlier: 2026-08-21 → 2026-06-29
Trial Details
NCT Number NCT07271251
Lead Sponsor Novo Nordisk A/S
Conditions Type 2 Diabetes
Enrollment 267 participants
Start Date 2025-12-01
Primary Completion 2026-06-29 (estimated)
Study Completion 2026-08-04 (estimated)
Updated on ClinicalTrials.gov 2026-08-13